Date: 2016-12-20
Type of information: IPO
Company: Tigenix (Belgium)
Investors:
Amount: $35.65 million
Funding type: IPO
Planned used:
Others:
- • On December 20, 2016, TiGenix announced the closing of its initial public offering in the United Statestotalling $35.65 million gross proceeds from the sale of 2,300,000 American Depository Shares, representing 46,000,000 ordinary shares, at a price to the public of $15.50 per ADS.
- Each of the ADSs offered represents the right to receive twenty (20) ordinary shares. The ADSs are listed on the NASDAQ Global Select Market under the symbol "TIG".
- • On December 15, 2016, TiGenix announced the pricing of its initial public offering in the United States totalling $35.65 million gross proceeds from the sale of 2,300,000 American Depository Shares, representing 46,000,000 ordinary shares, at a price to the public of $15.50 per ADS. In connection with the Offering, TiGenix has granted the underwriters a 30-day option to purchase up to an additional 345,000 ADSs, representing 6,900,000 ordinary shares, to cover over-allotments, if any. The closing of the Offering is expected to occur on December 20, 2016, subject to the satisfaction of customary closing conditions.
- • On December 5, 2016, TiGenix announced that it intends to offer and sell, subject to market and other conditions, 2.75 million American Depositary Shares representing 55 million ordinary shares in an initial public offering in the United States. The final issuance price per ADS (in USD) sold in the Offering will be determined following the bookbuilding process.
- TiGenix's ordinary shares are currently listed on Euronext Brussels. An application has been made to list the ADSs on the NASDAQ Global Market under the symbol "TIG". Application will also be made to admit the ordinary shares, underlying the ADSs, issued pursuant to the Offering to trading on Euronext Brussels.
- BofA Merrill Lynch and Cowen and Company, LLC are acting as joint book-running managers, Canaccord Genuity is acting as lead manager and BTIG is acting as co-manager for the proposed Offering.
- • On October 26, 2016, TiGenix announced the filing of an amendment to its registration statement on Form F-1 with the U.S. Securities and Exchange Commission for the proposed initial public offering in the United States of its American Depositary Shares, initially filed on December 22, 2015. The amendment includes a revised syndicate of underwriters for the proposed offering. The number and price of the ADSs to be offered will be determined if and when the initial public offering is launched.
- • On December 22, 2015, TiGenix announced that it has filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of its American Depository Shares to be listed on the NASDAQ Global Market in the United States. The number and price of the ADSs to be offered have not yet been determined.
Therapeutic area: Autoimmune diseases - Inflammatory diseases - Digestive diseases - Regenerative medicine
Is general: Yes
